

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

THERAVANCE BIOPHARMA R&D IP,  
LLC, THERAVANCE BIOPHARMA US,  
INC., THERAVANCE BIOPHARMA  
IRELAND LIMITED, MYLAN IRELAND  
LIMITED, and MYLAN SPECIALTY L.P.,

Plaintiffs,

v.

EUGIA PHARMA SPECIALITIES LTD.,  
EUGIA US LLC, AUROBINDO PHARMA  
USA, INC., AUROBINDO PHARMA  
LIMITED, MANKIND PHARMA LTD.,  
LIFESTAR PHARMA LLC, LUPIN INC.,  
LUPIN PHARMACEUTICALS, INC.,  
ORBICULAR PHARMACEUTICAL  
TECHNOLOGIES PRIVATE LIMITED,  
CIPLA LIMITED, and CIPLA USA, INC.,

Defendants.

Civil Action No. 1:24-cv-000150-KMW-AMD

**STIPULATED CONSENT JUDGMENT AND INJUNCTION**

IT IS HEREBY STIPULATED AND AGREED, by and between Plaintiffs Theravance Biopharma R&D IP, LLC, Theravance Biopharma US, Inc., Theravance Biopharma Ireland Limited, Mylan Ireland Limited, and Mylan Specialty L.P. (collectively, “Plaintiffs”) and Defendant Orbicular Pharmaceutical Technologies Private Limited (“Orbicular”) (Orbicular together with Plaintiffs, the “Parties”), through their undersigned counsel of record, that:

1. This Court has jurisdiction over the Parties and the subject matter of this action.
2. The Parties stipulate and agree that all claims, counterclaims, and affirmative defenses asserted by the Parties against each other in the above-captioned action are hereby dismissed without prejudice.

3. Orbicular and anyone acting on the behalf of Orbicular, except as licensed by Plaintiffs, will be enjoined until expiration of U.S. Patent No. 11,858,898 from making, using, offering to sell, selling or importing the products that are the subject of ANDA No. 217868 in the United States.

4. Nothing herein shall prevent FDA from granting final approval to Orbicular's ANDA No. 217868 at any time.

5. Each Party will bear its own attorneys' fees and costs.

6. This Court will retain jurisdiction to enforce this Stipulated Consent Judgment and Injunction and the Parties' related agreements resolving this matter.

Dated: January 12, 2024

s/ Arnold B. Calmann  
Arnold B. Calmann (abc@saiber.com)  
Katherine A. Escanlar  
(kescanlar@saiber.com)  
SAIBER LLC  
18 Columbia Turnpike  
Suite 200  
Florham Park, NJ 07932  
Telephone: (973) 622-3333

*Attorneys for Plaintiffs Theravance  
Biopharma R&D IP, LLC, Theravance  
Biopharma Ireland Limited, Theravance  
Biopharma US, Inc., Mylan Ireland Limited,  
and Mylan Specialty L.P.*

Of Counsel  
Mary W. Bourke (Mary.Bourke@wbd-  
us.com)  
Dana K. Severance (Dana.Severance@wbd-  
us.com)  
Ben Bourke (Ben.Bourke@wbd-us.com)

s/ Tedd W. Van Buskirk  
Tedd W. Van Buskirk  
DAIGNAULT IYER LLP  
8618 Westwood Center Drive, Suite 150  
Vienna, VA 22182  
tvanbuskirk@daignaultiyer.com

Richard Juang  
DAIGNAULT IYER LLP  
8618 Westwood Center Drive, Suite 150  
Vienna, VA 22182  
rjuang@daignaultiyer.com

*Attorneys for Defendant Orbicular  
Pharmaceutical Technologies Private Limited*


WOMBLE BOND DICKINSON (US) LLP  
1313 North Market Street, Suite 1200  
Wilmington, Delaware 19801  
(302) 252-4320

*Attorneys for Plaintiffs Theravance  
Biopharma R&D IP, LLC, Theravance  
Biopharma Ireland Limited, and Theravance  
Biopharma US, Inc.*

William A. Rakoczy  
(wrakoczy@rmmslegal.com)  
Kevin E. Warner (kwarner@rmmslegal.com)  
Joseph T. Jaros (jjaros@rmmslegal.com)  
Matthew V. Anderson  
(manderson@rmmslegal.com)  
RAKOCZY MOLINO MAZZOCHI SIWIK  
LLP  
6 West Hubbard Street, Suite 500  
Chicago, Illinois 60654  
(312) 527-2157

*Attorneys for Plaintiffs Mylan Ireland  
Limited and Mylan Specialty L.P.*

SO ORDERED this 26th day of Janauary, 2024

  
\_\_\_\_\_  
United States District Judge